Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26ClNO |
Molecular Weight | 343.89 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3
InChI
InChIKey=YNNUSGIPVFPVBX-NHCUHLMSSA-N
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00283Curator's Comment: Description was created based on several sources, including
http://www.sciencedirect.com/topics/page/Clemastine and https://www.drugs.com/pro/clemastine.html
Sources: http://www.drugbank.ca/drugs/DB00283
Curator's Comment: Description was created based on several sources, including
http://www.sciencedirect.com/topics/page/Clemastine and https://www.drugs.com/pro/clemastine.html
Clemastine is an antihistamine with anticholinergic (drying) and sedative side effects. Clemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL368 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25033456 |
0.4 µM [IC50] | ||
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16288909 |
12.0 nM [IC50] | ||
Target ID: CHEMBL289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9616188 |
2.0 µM [Ki] | ||
Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00283 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLEMASTINE Approved UseClemastine fumarate tablets are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation.
Clemastine fumarate tablets are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Launch Date1992 |
|||
Sources: https://www.drugs.com/pro/clemastine.html |
Primary | CLEMASTINE Approved UseClemastine fumarate tablets are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation.
Clemastine fumarate tablets are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Launch Date1992 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15664345/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
650 pg/mL |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1010 pg/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15664345/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
15529 pg × h/mL |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
26230 pg × h/mL |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15664345/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
17.28 h |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
23.94 h |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLEMASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
4 mg single, oral Highest studied dose |
healthy |
|
0.5 mg single, oral Dose: 0.5 mg Route: oral Route: single Dose: 0.5 mg Sources: |
healthy Health Status: healthy Sex: M+F Sources: |
Disc. AE: Itching, Rash... AEs leading to discontinuation/dose reduction: Itching (1 patient) Sources: Rash (1 patient) Nausea (1 patient) Pallor (1 patient) |
1 mg single, oral Dose: 1 mg Route: oral Route: single Dose: 1 mg Sources: |
healthy Health Status: healthy Sex: M Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Itching | 1 patient Disc. AE |
0.5 mg single, oral Dose: 0.5 mg Route: oral Route: single Dose: 0.5 mg Sources: |
healthy Health Status: healthy Sex: M+F Sources: |
Nausea | 1 patient Disc. AE |
0.5 mg single, oral Dose: 0.5 mg Route: oral Route: single Dose: 0.5 mg Sources: |
healthy Health Status: healthy Sex: M+F Sources: |
Pallor | 1 patient Disc. AE |
0.5 mg single, oral Dose: 0.5 mg Route: oral Route: single Dose: 0.5 mg Sources: |
healthy Health Status: healthy Sex: M+F Sources: |
Rash | 1 patient Disc. AE |
0.5 mg single, oral Dose: 0.5 mg Route: oral Route: single Dose: 0.5 mg Sources: |
healthy Health Status: healthy Sex: M+F Sources: |
Vomiting | 1 patient Disc. AE |
1 mg single, oral Dose: 1 mg Route: oral Route: single Dose: 1 mg Sources: |
healthy Health Status: healthy Sex: M Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Atrial T (Ta) loop in dogs with or without atrial injury. | 1976 May |
|
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. | 2002 |
|
[Comparative antihistamine and anti-allergic effects of various antihistamine preparations]. | 2002 |
|
[Stem cell factor production from cultured nasal epithelial cells--effect on SCF production by drugs]. | 2002 Feb |
|
[Severe adverse event following iv administration of 10 ml 6% Dextran60 (0.6 g) in a healthy volunteer]. | 2002 Oct |
|
Antihistamines in the management of canine atopic dermatitis: a retrospective study of 171 dogs (1992-1998). | 2002 Spring |
|
Pharmacokinetics and pharmacodynamics of clemastine in healthy horses. | 2003 Apr |
|
Role of histamine receptors in the regulation of edema and circulation postburn. | 2003 Dec |
|
IgA pemphigus occurring in a 1-month-old infant. | 2003 Feb |
|
Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. | 2003 Jan |
|
Why aren't lower, effective, OTC doses available earlier by prescription? | 2003 Jan |
|
Hypersensitivity vasculitis induced by cefoperazone/sulbactam. | 2003 Jan 3 |
|
[Tolerance induction in anaphylaxis to carboplatin]. | 2003 Jul 25 |
|
Serious allergic reaction to administration of epirubicin. | 2003 Jun |
|
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. | 2004 Jan 26 |
|
[Appearance diagnosis. Facial shingles]. | 2004 Jul 22 |
|
Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report. | 2004 Nov 2 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. | 2006 |
|
Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog. | 2006 Mar |
|
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. | 2006 Mar 13 |
|
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). | 2008 Aug 22 |
|
Major determinants and long-term outcomes of successful balloon dilatation for the pediatric patients with isolated native valvular pulmonary stenosis: a 10-year institutional experience. | 2008 Jun 30 |
|
Medication with antihistamines impairs allergen-specific immunotherapy in mice. | 2008 Mar |
|
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). | 2008 Nov 26 |
|
Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS). | 2008 Sep |
|
[Documentation for acute treatment with clemastine (Tavegyl) is missing]. | 2009 Jul 22-Aug 4 |
|
Psychoactive medication and traffic safety. | 2009 Mar |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. | 2010 Feb 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/clemastine.html
Usual Adult Dose for Allergic Rhinitis
Initial dose: 1.34 mg orally twice a day. Dosage may be increased as required, but not to exceed 2.68 mg orally 3 times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16288909
IHERG tails at -40 mV following depolarizing pulses to +20 mV were inhibited by clemastine with an IC50 value of 12 nM in HEK 293 cells
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD04AA14
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
WHO-VATC |
QR06AA04
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
LIVERTOX |
NBK548709
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
WHO-ATC |
R06AA54
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
WHO-VATC |
QR06AA54
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
WHO-ATC |
D04AA14
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
||
|
WHO-ATC |
R06AA04
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D002974
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
SUB06648MIG
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
2578
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
6063
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
DB00283
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
DTXSID2022832
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
26987
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
C61682
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
2231
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
CLEMASTINE
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
m3613
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
671
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL1626
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
756685
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
Clemastine
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
15686-51-8
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
100000080172
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
3738
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
95QN29S1ID
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY | |||
|
95QN29S1ID
Created by
admin on Mon Mar 31 17:53:45 GMT 2025 , Edited by admin on Mon Mar 31 17:53:45 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)